Sermorelin
29-residue GHRH analog. Studied as a research probe of the somatotropic axis.
Sermorelin is GRF(1-29) — the first 29 amino acids of native growth-hormone-releasing hormone, which turn out to be the shortest fragment retaining full activity at the GHRH receptor. It has been an endocrine-research staple for decades, long enough to have accumulated an unusually mature literature.
Because it reproduces native GHRH signaling with a short half-life, sermorelin is the classic tool for studying pulsatile GH release and pituitary responsiveness — experiments where a long-acting analog would flatten exactly the dynamics under investigation.
Its long history also makes it one of the best-characterized peptides for identity verification. Bench Grade lots are HPLC-verified with published Certificates of Analysis.
Published research
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiencyPrakash A, et al. BioDrugs. 1999.PubMed →
- Continuous subcutaneous GHRH(1-29)NH2 promotes growth over 1 year in short, slowly growing childrenThorner M, et al. J Clin Endocrinol Metab. 1990.PubMed →
Further reading in the lab library
Researchers also ordered
- CJC-1295 (no DAC)Modified GHRH (1-29) analog without drug-affinity complex. Short half-life GH-axis research peptide.
- IpamorelinSelective GHSR-1a agonist pentapeptide. Studied in pulsatile GH-release research.
- TesamorelinStabilized GHRH analog studied in lipodystrophy and visceral-adiposity research models.